Cargando…
PD-L1 expression is associated with advanced non-small cell lung cancer
Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (P...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/ https://www.ncbi.nlm.nih.gov/pubmed/27446371 http://dx.doi.org/10.3892/ol.2016.4741 |
_version_ | 1782443567978905600 |
---|---|
author | Chen, Zhiquan Mei, Jiandong Liu, Lunxu Wang, Guochen Li, Zuosheng Hou, Jingpu Zhang, Qiuyang You, Zongbing Zhang, Liu |
author_facet | Chen, Zhiquan Mei, Jiandong Liu, Lunxu Wang, Guochen Li, Zuosheng Hou, Jingpu Zhang, Qiuyang You, Zongbing Zhang, Liu |
author_sort | Chen, Zhiquan |
collection | PubMed |
description | Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (PD-L1) have been tested in clinical trials, and anti-PD-1 antibody has been approved for the treatment of NSCLC. The aim of the present study was to assess expression of PD-1, PD-L1 and programmed cell death protein 1 ligand 2 (PD-L2) in 48 patients with NSCLC, using immunohistochemical staining. The results found that 35.4% (17/48) of patients were positive for PD-1 expression, 64.6% (31/48) were positive for PD-L1 expression and 45.8% (22/48) were positive for PD-L2 expression. Neither PD-1 nor PD-L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD-L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis; however, PD-L1 expression was significantly increased in stage III NSCLC (85.7% PD-L1+) compared with stage I/II NSCLC (55.9% PD-L1+) (P=0.049). |
format | Online Article Text |
id | pubmed-4950525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-49505252016-07-21 PD-L1 expression is associated with advanced non-small cell lung cancer Chen, Zhiquan Mei, Jiandong Liu, Lunxu Wang, Guochen Li, Zuosheng Hou, Jingpu Zhang, Qiuyang You, Zongbing Zhang, Liu Oncol Lett Articles Lung cancer is the most common cause of cancer-associated mortalities worldwide. Novel immunotherapies have been developed to improve the clinical outcomes of non-small cell lung cancer (NSCLC). Antibodies against programmed cell death protein 1 (PD-1) and programmed cell death protein 1 ligand 1 (PD-L1) have been tested in clinical trials, and anti-PD-1 antibody has been approved for the treatment of NSCLC. The aim of the present study was to assess expression of PD-1, PD-L1 and programmed cell death protein 1 ligand 2 (PD-L2) in 48 patients with NSCLC, using immunohistochemical staining. The results found that 35.4% (17/48) of patients were positive for PD-1 expression, 64.6% (31/48) were positive for PD-L1 expression and 45.8% (22/48) were positive for PD-L2 expression. Neither PD-1 nor PD-L2 expression was associated with gender, histology, differentiation status, tumor stage or lymph node metastasis. PD-L1 expression was not associated with gender, histology, differentiation status or lymph node metastasis; however, PD-L1 expression was significantly increased in stage III NSCLC (85.7% PD-L1+) compared with stage I/II NSCLC (55.9% PD-L1+) (P=0.049). D.A. Spandidos 2016-08 2016-06-16 /pmc/articles/PMC4950525/ /pubmed/27446371 http://dx.doi.org/10.3892/ol.2016.4741 Text en Copyright: © Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Chen, Zhiquan Mei, Jiandong Liu, Lunxu Wang, Guochen Li, Zuosheng Hou, Jingpu Zhang, Qiuyang You, Zongbing Zhang, Liu PD-L1 expression is associated with advanced non-small cell lung cancer |
title | PD-L1 expression is associated with advanced non-small cell lung cancer |
title_full | PD-L1 expression is associated with advanced non-small cell lung cancer |
title_fullStr | PD-L1 expression is associated with advanced non-small cell lung cancer |
title_full_unstemmed | PD-L1 expression is associated with advanced non-small cell lung cancer |
title_short | PD-L1 expression is associated with advanced non-small cell lung cancer |
title_sort | pd-l1 expression is associated with advanced non-small cell lung cancer |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950525/ https://www.ncbi.nlm.nih.gov/pubmed/27446371 http://dx.doi.org/10.3892/ol.2016.4741 |
work_keys_str_mv | AT chenzhiquan pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT meijiandong pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT liulunxu pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT wangguochen pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT lizuosheng pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT houjingpu pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT zhangqiuyang pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT youzongbing pdl1expressionisassociatedwithadvancednonsmallcelllungcancer AT zhangliu pdl1expressionisassociatedwithadvancednonsmallcelllungcancer |